Related references
Note: Only part of the references are listed.Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
John A. Wells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Long-term Effects of Therapy with Ranibizumab on Diabetic Retinopathy Severity and Baseline Risk Factors for Worsening Retinopathy
Michael S. Ip et al.
OPHTHALMOLOGY (2015)
Revolution to a New Standard Treatment of Diabetic Macular Edema
Lee M. Jampol et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Safety and Efficacy of Conbercept in Neovascular Age-Related Macular Degeneration Results from a 12-Month Randomized Phase 2 Study: AURORA Study
Xiaoxin Li et al.
OPHTHALMOLOGY (2014)
Intravitreal Aflibercept for Diabetic Macular Edema
Jean-Francois Korobelnik et al.
OPHTHALMOLOGY (2014)
Diabetic macular edema: new concepts in patho-physiology and treatment
Xinyuan Zhang et al.
CELL AND BIOSCIENCE (2014)
Underuse of the Health Care System by Persons With Diabetes Mellitus and Diabetic Macular Edema in the United States
Neil M. Bressler et al.
JAMA OPHTHALMOLOGY (2014)
Evaluation of Results 1 Year Following Short-term Use of Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Abdhish R. Bhavsar et al.
JAMA OPHTHALMOLOGY (2014)
Therapies for Neovascular Age-Related Macular Degeneration: Current Approaches and Pharmacologic Agents in Development
Mostafa Hanout et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Saline for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy Diabetic Retinopathy Clinical Research Network
Abdhish R. Bhavsar et al.
JAMA OPHTHALMOLOGY (2013)
A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema 24-Month Data: Report 3
Ranjan Rajendram et al.
ARCHIVES OF OPHTHALMOLOGY (2012)
Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression
Michael S. Ip et al.
ARCHIVES OF OPHTHALMOLOGY (2012)
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment Three-Year Randomized Trial Results
Michael J. Elman et al.
OPHTHALMOLOGY (2012)
Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Michael J. Elman et al.
OPHTHALMOLOGY (2011)
A Phase 1 Study of KH902, a Vascular Endothelial Growth Factor Receptor Decoy, for Exudative Age-Related Macular Degeneration
Ming Zhang et al.
OPHTHALMOLOGY (2011)
Rationale for the Diabetic Retinopathy Clinical Research Network Treatment Protocol for Center-Involved Diabetic Macular Edema
Lloyd Paul Aiello et al.
OPHTHALMOLOGY (2011)
RANDOMIZEDTRIAL EVALUATING SHORT-TERM EFFECTS OF INTRAVITREAL RANIBIZUMAB OR TRIAMCINOLONE ACETONIDE ON MACULAR EDEMA AFTER FOCAL/GRID LASER FOR DIABETIC MACULAR EDEMA IN EYES ALSO RECEIVING PANRETINAL PHOTOCOAGULATION
Joseph Googe et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2011)
A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study) 12-Month Data: Report 2
Michel Michaelides et al.
OPHTHALMOLOGY (2010)
Vascular endothelial growth factor-A: A multifunctional molecular player in diabetic retinopathy
Xinyuan Zhang et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration - The 50-year medalist study
Hillary A. Keenan et al.
DIABETES CARE (2007)
Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment
Robert L. Avery
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2006)
Characteristics of Type 1 diabetes of over 50 years duration (the Golden Years Cohort)
SC Bain et al.
DIABETIC MEDICINE (2003)
Share Paper
